브루셀라증 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Brucellosis Vaccines Market size is expected to reach USD 1.56 Billion in 2034 from USD 0.86 Billion (2025) growing at a CAGR of 6.79% during 2026-2034.

The global brucellosis vaccines market has gained attention due to increasing efforts to control this infectious disease that affects livestock and can also infect humans. Brucellosis causes reproductive problems in animals and economic losses in the agricultural sector. Vaccination plays a critical role in preventing disease spread and protecting livestock populations.

Several factors are driving the growth of the brucellosis vaccines market. Rising demand for livestock health management and improved animal productivity has encouraged farmers and governments to adopt vaccination programs. Additionally, growing awareness about zoonotic diseases and their impact on public health has increased the importance of effective disease prevention strategies.

In the future, the brucellosis vaccines market is expected to grow as governments strengthen animal disease control programs. Advances in veterinary vaccine development may improve vaccine effectiveness and safety. Furthermore, increasing investments in animal health research and agricultural productivity will likely support long-term market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• RBS1
• S19
• B19

By Vaccine

• DNA Vaccine
• Subunit Vaccine
• Vector Vaccine
• Recombinant Vaccine

By Animal Type

• Cattle
• Sheep
• Goat

By End User

• Veterinary Hospitals and Clinics
• Animal Care Centers
• Other

COMPANIES PROFILED

• Creative Biolabs, Laboratories Tornel, Hester Biosciences Limited, Merck Co Inc, CZ Vaccines, Ceva Poultry, Fivet Animal Health, Colorado Serum Company, Indian Immunologicals Ltd, Jordan Bioindustries Center
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BRUCELLOSIS VACCINES MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. RBS1 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. S19 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. B19 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL BRUCELLOSIS VACCINES MARKET: BY VACCINE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Vaccine
• 5.2. DNA Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Subunit Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Vector Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Recombinant Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL BRUCELLOSIS VACCINES MARKET: BY ANIMAL TYPE 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Animal Type
• 6.2. Cattle Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Sheep Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Goat Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL BRUCELLOSIS VACCINES MARKET: BY END USER 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Veterinary Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Animal Care Centers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL BRUCELLOSIS VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.2.1 By Type
  • 8.2.2 By Vaccine
  • 8.2.3 By Animal Type
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.3.1 By Type
  • 8.3.2 By Vaccine
  • 8.3.3 By Animal Type
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.4.1 By Type
  • 8.4.2 By Vaccine
  • 8.4.3 By Animal Type
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.5.1 By Type
  • 8.5.2 By Vaccine
  • 8.5.3 By Animal Type
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.6.1 By Type
  • 8.6.2 By Vaccine
  • 8.6.3 By Animal Type
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BRUCELLOSIS VACCINES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Creative Biolabs
  • 10.2.2 Laboratories Tornel
  • 10.2.3 Hester Biosciences Limited
  • 10.2.4 Merck & Co. Inc
  • 10.2.5 CZ Vaccines
  • 10.2.6 Ceva Poultry
  • 10.2.7 Fivet Animal Health
  • 10.2.8 Colorado Serum Company
  • 10.2.9 Indian Immunologicals Ltd
  • 10.2.10 Jordan Bio-Industries Center